ClinicalTrials.gg
Not yet recruitingNCT07936838Updated Nov 13, 2026

Effects of a Gut-Active Peptide That Stimulates GLP-1 Release on Appetite and Satiety in Healthy Adults With Overweight

An interventional study of Lembas Edge™ and Placebo in Appetite and Hunger, Suppression, Satiety and Appetite and Weight Change, sponsored by Lembas. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Lembas · Not applicable, Interventional, and Basic science

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 113 studies in Body Weight Changes with a site in United States — 12 open to participants now, 17 under way, 2 of them phase 3. Body Weight Changes · United States.

Planned enrollment
28th of 95
150 · median 60
Started
2026
with 4 others
No phase
73 of 113
8 open now
Primary completion
2027-07
later than 9 of 16 live
Registered
113th of 113
by date

Among the 113 studies in Body Weight Changes with a site in United States, this one is the 28th largest by planned enrollment of the 95 interventional ones that give a count, is one of 5 that started in 2026, is one of 73 with no phase, reaches primary completion later than 9 of the 16 other live ones, and was the 113th registered.

Body Weight Changes

232 studies on the registry are indexed under Body Weight Changes; 31 are open to participants now.

Browse Body Weight Changes studies →

Open to participants now

12 of the 113 studies in Body Weight Changes with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Body Weight Changes studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Body Weight Changes with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to see if a daily supplement called Lembas Edge™ helps control appetite and fullness in healthy adults who are overweight. The main questions it aims to answer are:

  1. Does taking Lembas Edge™ help reduce hunger and improve feelings of fullness (appetite and satiety)?
  2. How does the supplement affect body weight, body mass index (BMI), waist size, food cravings ("food noise"), and digestion?

Researchers will compare two different doses of Lembas Edge™ to a placebo (a pill that looks identical but contains no active supplement) to see how well it works.

Participants will be asked to:

  1. Take the study supplement or placebo twice a day (once in the morning and once in the afternoon) for 6 months, with an option to continue in an "open label extension" for an extra 3 months
  2. Log their daily meals and snacks and confirm when they take their product using a smartphone app
  3. Weigh themselves and check their body composition weekly using a special scale provided by the study
  4. Answer weekly and monthly surveys about their hunger levels, food thoughts, digestion, and any health symptoms
Read the detailed description

The rationale for this study is to observe safe, well-tolerated nutritional intervention that support appetite regulation, satiety, and long-term weight control. The current study aims to evaluate the impact of an investigational supplement, Lembas Edge™, on satiety-related outcomes and body weight relevant to weight management in overweight and mildly obese healthy adults. The safety profile will be measured via activities and technologies that can successfully and effectively be completed and utilized in a home setting.

03

Conditions studied

  • Appetite and Hunger, Suppression
  • Satiety and Appetite
  • Weight Change
  • Gastrointestinal Symptoms
  • Body Composition

Keywords

  • weight loss
  • GLP-1
  • supplement
  • appetite regulation
  • weight management
  • food noise
  • home-based study
  • obesity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals 18-65 years of age
  2. Individuals with a of 25-35 kg/m2 from self-reported weight and height measured within the last 6 months prior to randomization
  3. In good general health at the time of screening (Investigator discretion).
  4. Able to read and understand English and provide .
  5. Able to use a personal smartphone device and download Chloe by People Science
  6. Able to receive shipment of the product at an address within the United States.
  7. Able to complete study assessments over the course of up to 30 weeks.
  8. Willing to measure weight weekly using provisioned bioimpedance scale.

Exclusion criteria

Exclusion Criteria:

  1. Do not have a personal smartphone, internet access, or unwilling to download Chloe.
  2. Concomitant Therapies: Participants receiving any of the following treatments or therapies are excluded:

2a. Any therapies or treatments (pharmaceuticals, devices, supplements) within 90 days prior to randomization.

2b. Treatment with Glucagon-like peptide-1 (GLP-1) agonists (Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro, Zepbound), Liraglutide (Victoza, Saxenda), Dulaglutide (Trulicity), Exenatide (Byetta, Bydureon BCise), Orforglipon, Cagrilintine/Semaglutide (CagriSema)) within the last 90 days prior to randomization.

3. Other Illnesses or Conditions: Participants who have the following comorbidities or gastrointestinal illnesses (GI) are excluded: 3a. Currently diagnosed with Type I or Type II Diabetes 3b. Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder 3c. Currently pregnant, planning to become pregnant in the next 9 months, or breastfeeding 3d. History of bariatric or other significant gastrointestinal surgery (e.g., small bowel resection, total colectomy) that has permanently altered GI anatomy or function. Standard appendectomy or cholecystectomy are generally permitted.

3e. Any underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes 3f. New diagnosis workup planned during study that may change diagnosis/ behavior/ medications (eg. colonoscopy prep or major bowel cleanse, upcoming GI consult that could affect eligibility).

3g. Have a significant illness, disease or condition which, in the opinion of the Principal Investigator, may impact their ability to participate in the study or impact the study outcomes.

4. Participants who are on, plan to initiate, or have recently completed (within the last 3 months) a major restrictive or elimination diet, or a structured weight-loss diet (i.e keto diet, pure carnivore diet, raw food diet, fruitarian diet, liquid diet) during the study period.

5. Use of any antibiotics, antifungals, or antivirals within 2 weeks prior to randomization.

6. Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator 7. Allergy (including alpha-gal syndrome), sensitivity, intolerance, or dietary restriction preventing consumption of investigational product or placebo ingredients 8. Implanted electronic devices, such as a cardiac pacemaker, cochlear implant, or an implanted defibrillator, that might be for use with the bioimpedance scale used in the study (nonelectronic metal implants such as nails, screws, plates, metal braces are OK)

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Study Product High Dose

    Dietary Supplement: Lembas Edge™

  • Active comparator
    Study Product Medium Dose

    Dietary Supplement: Lembas Edge™

  • Placebo comparator
    Placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementLembas Edge™

    Lembas Edge™ is a supplement containing a naturally-derived amino acid peptide fragment, which has been previously studied in gastrointestinal applications and demonstrated a well-established safety profile.

  • Dietary supplementPlacebo

    A placebo supplement that looks and tastes like the study product but does not any active ingredients.

06

What researchers measure

Primary outcomes

  1. Change in the Flint Visual Analogue Scale (VAS) score as measured by the change in the appetite assessment score between study product and placebo groups. Baseline period will be compared as well.

    The Flint Visual Analogue Scale (VAS) consists of 8 questions scored from 0 to 100. Each question uses a slider where the left and right endpoints represent opposite extremes of hunger, fullness, and specific food cravings.

    Time frame: From Baseline to the end of the Product/Placebo Use Period (6 months)

Secondary outcomes

  1. Change in Gastrointestinal Symptom Rating Scale (GSRS) score at the end of 6 months between study product and placebo groups. Baseline period will be compared as well.

    The Gastrointestinal Symptom Rating Scale is a 15-item questionnaire that participants complete about digestive symptoms over the past week (reflux, abdominal pain, indigestion, diarrhea and constipation). Each item is scored from 1 (no discomfort) to 7 (very severe discomfort). Higher scores mean worse symptoms.

    Time frame: From Baseline to the end of the Product/Placebo Use Period (6 months)

  2. Change from baseline in waist-to-height ratio (WtHR) using provisioned tape at the end of 6 months between study product and placebo groups.

    A body tape measure and a height ruler is provided to measure waist circumference and height. A higher ratio means a larger waist relative to height.

    Time frame: From Baseline to the end of the Product/Placebo Use Period (6 months)

  3. Change in Ro Allison Indiana Dhurandhar Food Noise (RAID-FN) Inventory score at the end of 6 months between study product and placebo groups, as well as trend over time. Baseline period will be compared as well.

    The RAID-FN measure "food noise" intensity and contains 29 items total, ranking items on a 5-point Likert scale.

    Time frame: From Baseline to the end of the Product/Placebo Use Period (6 months)

  4. Change from baseline in weight and BMI using a provisioned scale at the end of 6 months between study product and placebo groups

    Body mass index is calculated automatically from weight and height captured by a study-provided scale and self-measured height.

    Time frame: From Baseline to the end of the Product/Placebo Use Period (6 months)

Other outcomes

  1. Assessment of patient satisfaction survey of study experience including design and use of app-based data collection tools

    Time frame: End of the Product/Placebo Use Period (Month 6)

  2. Change from baseline in body composition analysis using a provisioned bioimpedance scale at the end of 6 months between study product and placebo groups.

    Participants measure body composition (such as body fat, muscle mass and body water) on a study-provided bioimpedance scale.

    Time frame: From Baseline to the end of the Product/Placebo Use Period (6 months)

07

Study locations

1 site
08

References and documents

Publications

  • Wang Y, Beydoun MA, Min J, Xue H, Kaminsky LA, Cheskin LJ. Has the prevalence of overweight, obesity and central obesity levelled off in the United States? Trends, patterns, disparities, and future projections for the obesity epidemic. Int J Epidemiol. 2020 Jun 1;49(3):810-823. doi: 10.1093/ije/dyz273. PubMed 32016289 ↗
  • Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29(1):71-83. doi: 10.1016/0022-3999(85)90010-8. PubMed 3981480 ↗
  • Schneider KL, Bodenlos JS, Ma Y, Olendzki B, Oleski J, Merriam P, Crawford S, Ockene IS, Pagoto SL. Design and methods for a randomized clinical trial treating comorbid obesity and major depressive disorder. BMC Psychiatry. 2008 Sep 15;8:77. doi: 10.1186/1471-244X-8-77. PubMed 18793398 ↗
  • Kulich KR, Madisch A, Pacini F, Pique JM, Regula J, Van Rensburg CJ, Ujszaszy L, Carlsson J, Halling K, Wiklund IK. Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes. 2008 Jan 31;6:12. doi: 10.1186/1477-7525-6-12. PubMed 18237386 ↗
  • Karlsson J, Persson LO, Sjostrom L, Sullivan M. Psychometric properties and factor structure of the Three-Factor Eating Questionnaire (TFEQ) in obese men and women. Results from the Swedish Obese Subjects (SOS) study. Int J Obes Relat Metab Disord. 2000 Dec;24(12):1715-25. doi: 10.1038/sj.ijo.0801442. PubMed 11126230 ↗
  • Caballero B. Humans against Obesity: Who Will Win? Adv Nutr. 2019 Jan 1;10(suppl_1):S4-S9. doi: 10.1093/advances/nmy055. PubMed 30721956 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in the primary publication will be shared on request. The informed consent form will also be available.

Supporting information: Informed consent form

Time frame: Beginning 6 months after publication of the primary results, for 5 years.

Access criteria: Qualified researchers who submit a methodologically sound proposal to the study contact and sign a data use agreement. Requesters may bear the cost of preparing and transferring the data.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.

Of 99 interventional studies with no phase under Body Weight Changes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2026
First posted
Nov 13, 2026
StartEst.
Nov 2026
Primary completionEst.
Jul 2027
CompletionEst.
Oct 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07936838
Lead sponsor
Lembas
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Clinical Research Project Manager
Contact
ps44lembasedgestudy@peoplescience.health
(213) 785-7755

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion